NCT06892704View on ClinicalTrials.gov

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2027

Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)Smell Loss
Interventions
DRUG

Dupilumab - Standard Dose

24 weeks of dupilumab 300mg q2 weeks

Trial Locations (1)

60611

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Northwestern University

OTHER